Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume
Background: Currently, the combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapy is a first-line treatment for hormone-receptor-positive and HER2-negative metastatic breast cancer. This study aimed to assess the impact of changes in Mean Corpuscular Volume (MCV) on pre...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-09-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/10/424 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850205123254419456 |
|---|---|
| author | Bediz Kurt İnci Pınar Kubilay Tolunay Şura Öztekin Ergin Aydemir İrem Öner Öztürk Ateş Cengiz Karaçin |
| author_facet | Bediz Kurt İnci Pınar Kubilay Tolunay Şura Öztekin Ergin Aydemir İrem Öner Öztürk Ateş Cengiz Karaçin |
| author_sort | Bediz Kurt İnci |
| collection | DOAJ |
| description | Background: Currently, the combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapy is a first-line treatment for hormone-receptor-positive and HER2-negative metastatic breast cancer. This study aimed to assess the impact of changes in Mean Corpuscular Volume (MCV) on predicting responses to treatment and survival in patients with hormone-receptor-positive, HER2-negative metastatic breast cancer receiving CDK4/6 inhibitors and endocrine therapy. Methods: Retrospectively, data on hemoglobin levels, MCV, B12, folate levels, and survival times were collected from 275 patients. Patients were categorized into two groups based on the degree of MCV change (delta MCV ≤ 10 vs. >10). Kaplan–Meier survival analysis was performed, with significance set at <i>p</i> < 0.05. Results: The average age of the patients was 56.1 ± 12.1 years. In total, 72.7% received CDK4/6 inhibitors as first-line treatment, while 27.3% received them as second-line treatment. Before CDK4/6 inhibitor use, the median MCV level was 87.7 fL (IQR: 83–91), which increased to 98 fL (IQR: 92–103) after treatment (<i>p</i> < 0.001). ECOG performance score, CDK4/6 inhibitor treatment line, type of endocrine therapy, and MCV change were identified as independent predictors of progression-free survival in the Cox regression model. The median progression-free survival for the entire group was 28 months. Patients with MCV delta > 10 had a median progression-free survival of 33 months, compared to 23 months for those with MCV delta ≤ 10 (<i>p</i> = 0.029). There was no significant difference in median overall survival times between the two groups (<i>p</i> = 0.158). Conclusion: This study highlights that patients with MCV delta > 10 had longer median progression-free survival compared to those with MCV delta ≤ 10. |
| format | Article |
| id | doaj-art-a433ba64f8604e4fafa1869340c79037 |
| institution | OA Journals |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-a433ba64f8604e4fafa1869340c790372025-08-20T02:11:09ZengMDPI AGCurrent Oncology1198-00521718-77292024-09-0131105722572910.3390/curroncol31100424Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular VolumeBediz Kurt İnci0Pınar Kubilay Tolunay1Şura Öztekin2Ergin Aydemir3İrem Öner4Öztürk Ateş5Cengiz Karaçin6Dr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ankara 06560, TürkiyeDr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ankara 06560, TürkiyeDr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ankara 06560, TürkiyeDr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ankara 06560, TürkiyeDr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ankara 06560, TürkiyeDr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ankara 06560, TürkiyeDr. Abdurrahman Yurtaslan Ankara Oncology Hospital, Ankara 06560, TürkiyeBackground: Currently, the combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapy is a first-line treatment for hormone-receptor-positive and HER2-negative metastatic breast cancer. This study aimed to assess the impact of changes in Mean Corpuscular Volume (MCV) on predicting responses to treatment and survival in patients with hormone-receptor-positive, HER2-negative metastatic breast cancer receiving CDK4/6 inhibitors and endocrine therapy. Methods: Retrospectively, data on hemoglobin levels, MCV, B12, folate levels, and survival times were collected from 275 patients. Patients were categorized into two groups based on the degree of MCV change (delta MCV ≤ 10 vs. >10). Kaplan–Meier survival analysis was performed, with significance set at <i>p</i> < 0.05. Results: The average age of the patients was 56.1 ± 12.1 years. In total, 72.7% received CDK4/6 inhibitors as first-line treatment, while 27.3% received them as second-line treatment. Before CDK4/6 inhibitor use, the median MCV level was 87.7 fL (IQR: 83–91), which increased to 98 fL (IQR: 92–103) after treatment (<i>p</i> < 0.001). ECOG performance score, CDK4/6 inhibitor treatment line, type of endocrine therapy, and MCV change were identified as independent predictors of progression-free survival in the Cox regression model. The median progression-free survival for the entire group was 28 months. Patients with MCV delta > 10 had a median progression-free survival of 33 months, compared to 23 months for those with MCV delta ≤ 10 (<i>p</i> = 0.029). There was no significant difference in median overall survival times between the two groups (<i>p</i> = 0.158). Conclusion: This study highlights that patients with MCV delta > 10 had longer median progression-free survival compared to those with MCV delta ≤ 10.https://www.mdpi.com/1718-7729/31/10/424mean corpuscular volumeCDK4/6palbociclibribociclib |
| spellingShingle | Bediz Kurt İnci Pınar Kubilay Tolunay Şura Öztekin Ergin Aydemir İrem Öner Öztürk Ateş Cengiz Karaçin Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume Current Oncology mean corpuscular volume CDK4/6 palbociclib ribociclib |
| title | Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume |
| title_full | Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume |
| title_fullStr | Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume |
| title_full_unstemmed | Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume |
| title_short | Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume |
| title_sort | monitoring the response of cyclin dependent kinase 4 6 inhibitors with mean corpuscular volume |
| topic | mean corpuscular volume CDK4/6 palbociclib ribociclib |
| url | https://www.mdpi.com/1718-7729/31/10/424 |
| work_keys_str_mv | AT bedizkurtinci monitoringtheresponseofcyclindependentkinase46inhibitorswithmeancorpuscularvolume AT pınarkubilaytolunay monitoringtheresponseofcyclindependentkinase46inhibitorswithmeancorpuscularvolume AT suraoztekin monitoringtheresponseofcyclindependentkinase46inhibitorswithmeancorpuscularvolume AT erginaydemir monitoringtheresponseofcyclindependentkinase46inhibitorswithmeancorpuscularvolume AT iremoner monitoringtheresponseofcyclindependentkinase46inhibitorswithmeancorpuscularvolume AT ozturkates monitoringtheresponseofcyclindependentkinase46inhibitorswithmeancorpuscularvolume AT cengizkaracin monitoringtheresponseofcyclindependentkinase46inhibitorswithmeancorpuscularvolume |